Q-omics provides the consensus-scored ADAMTSL2 profile across patient tissues and cancer cell-line models. ADAMTSL2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ADAMTSL2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ADAMTSL2 RNA expression shows 24,894 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where ADAMTSL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTSL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTSL2 survival associations across molecular data types. ADAMTSL2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTSL2 RNA expression–survival associations across cancer types. High ADAMTSL2 expression shows unfavorable associations in KIRP, COAD and LUSC, but favorable associations in KIRC, LUAD and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for ADAMTSL2 RNA expression.
This table summarizes ADAMTSL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ADAMTSL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTSL2 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in HNSC, COAD and BRCA. The HNSC box plot shows higher ADAMTSL2 RNA expression in tumor versus normal tissue (log2 FC = +2.305, t-test p < 0.001).
This table shows molecular features associated with ADAMTSL2 in patient tissues and cancer cell lines. In patient samples, ADAMTSL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTSL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
